Summary of COVID-19 mebendazole studies
Hide extended summaries
RCT 69 outpatients in Jordan, showing improved viral clearance and CRP with mebendazole. Authors note that mebendazole, like ivermectin, has been shown to have antiviral activity against multiple viruses.
May 2023, Pharmaceuticals, https://www.mdpi.com/1424-8247/16/6/799, https://c19p.org/eltananimb
Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outpatient and inpatient results are listed separately [Galal, Galal].
Dec 2022, Advances in Virology, https://www.hindawi.com/journals/av/2022/3014686/, https://c19p.org/galal2
Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outpatient and inpatient results are listed separately [Galal, Galal].
Dec 2022, Advances in Virology, https://www.hindawi.com/journals/av/2022/3014686/, https://c19p.org/galalmb
1. El-Tanani et al., Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients
69 patient mebendazole early treatment RCT: 85% improved viral clearance (p=0.04).RCT 69 outpatients in Jordan, showing improved viral clearance and CRP with mebendazole. Authors note that mebendazole, like ivermectin, has been shown to have antiviral activity against multiple viruses.
May 2023, Pharmaceuticals, https://www.mdpi.com/1424-8247/16/6/799, https://c19p.org/eltananimb
2. Galal et al., The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study
157 patient mebendazole late treatment study: 51% lower mortality (p=0.35), 63% lower ventilation (p=0.3), and 30% shorter hospitalization (p=0.001).Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outpatient and inpatient results are listed separately [Galal, Galal].
Dec 2022, Advances in Virology, https://www.hindawi.com/journals/av/2022/3014686/, https://c19p.org/galal2
3. Galal et al., The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study
185 patient mebendazole early treatment study: 52% lower hospitalization (p=0.33) and 43% faster recovery (p=0.001).Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outpatient and inpatient results are listed separately [Galal, Galal].
Dec 2022, Advances in Virology, https://www.hindawi.com/journals/av/2022/3014686/, https://c19p.org/galalmb
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.